Aspirin as secondary prevention in patients with colorectal cancer: An unselected population-based study

Journal of Clinical Oncology

Volumn 34, Issue 21, 2016, Pages 2501-2508

  Bains, Simer J ^a,d   Mahic, Milada ^b   Myklebust, Tor Åge ^c   Småstuen, Milada Cvancarova ^d   Yaqub, Sheraz ^d   Dørum, Liv Marit ^c   Bjørnbeth, Bjørn Atle ^d   Møller, Bjørn ^c   Brudvik, Kristoffer Watten ^d   Taskén, Kjetil ^a,d  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; AGED; ARTICLE; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; TUMOR LOCALIZATION; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SECONDARY PREVENTION; STATISTICAL BIAS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; BIAS (EPIDEMIOLOGY); COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SECONDARY PREVENTION;

EID: 84978208271     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.3519     Document Type: Article

References (30)

1. World Health Organization. Globocan 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Geneva, Switzerland, World Health Organization, 2014
2. Cancer Registry of Norway. Cancer in Norway,2012. Oslo, Norway, Cancer Registry of Norway
3. Rothwell PM, Wilson M, Elwin CE, et al: Longterm effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
4. Rothwell PM, Wilson M, Price JF, et al: Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet 379:1591-1601, 2012
5. Cuzick J, Thorat MA, Bosetti C, et al: Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47-57, 2014
6. Gorelick PB, Weisman SM: Risk of hemorrhagic stroke with aspirin use: An update. Stroke 36: 1801-1807, 2005
7. Duggan JM: Gastrointestinal toxicity of minor analgesics. Br J Clin Pharmacol 10:407S-410S, 1980
8. World Health Organization. International Classification of Diseases for Oncology, 3rd revision (ICD-O-3). Geneva, Switzerland, World Health Organization, 2000
9. Furu K: Establishment of the nationwide Norwegian Prescription Database (NorPD): New opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi 18:129-136, 2008
10. Larsen IK, Småstuen M, Johannesen TB, et al: Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timeliness. Eur J Cancer 45:1218-1231, 2009
11. Statistics Norway. Oslo, Norway, Statistics Norway, 2014
12. Ministry of Health and Care Services. Act 2001-05-18-24: Personal Health Data Filing System Act-Act relating to personal health data filing systems and the processing of personal health data. Oslo, Norway, Ministry of Health and Care Services, 2014
13. Lytras T, Nikolopoulos G, Bonovas S: Statins and the risk of colorectal cancer: An updated systematic review and meta-analysis of 40 studies. World J Gastroenterol 20:1858-1870, 2014
14. Mansouri D, McMillan DC, Roxburgh CS, et al: The impact of aspirin, statins, and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br J Cancer 109:249-256, 2013
15. Engineer DR, Burney BO, Hayes TG, et al: Exposure to ACEI/ARB and b-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol 6:539-545, 2013
16. Kubota M, Shimizu M, Sakai H, et al: Reninangiotensin system inhibitors suppress azoxymethaneinduced colonic preneoplastic lesions in C57BL/KsJ-db/ db obese mice. Biochem Biophys Res Commun 410: 108-113, 2011
17. Li P, Wu H, Zhang H, et al: Aspirin use after diagnosis but not prediagnosis improves establishedcolorectal cancer survival: A meta-analysis. Gut 64: 1419-1425, 2014
18. Ye XF, Wang J, Shi WT, et al: Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: A meta-analysis of observational studies. Br J Cancer 111:2172-2179, 2014
19. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658, 2009
20. Reimers MS, Bastiaannet E, Langley RE, et al: Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med 174:732-739, 2014
21. Bastiaannet E, Sampieri K, Dekkers OM, et al: Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 106:1564-1570, 2012
22. Reimers MS, Bastiaannet E, van Herk-Sukel MP, et al: Aspirin use after diagnosis improves survival in older adults with colon cancer: A retrospective cohort study. J Am Geriatr Soc 60: 2232-2236, 2012
23. McCowan C, Munro AJ, Donnan PT, et al: Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 49:1049-1057, 2013
24. Cardwell CR, Kunzmann AT, Cantwell MM, et al: Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: A casecontrol analysis of a population-based cohort. Gastroenterology 146:700-708.e2, 2014
25. Liao X, Lochhead P, Nishihara R, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 367:1596-1606, 2012
26. Goh CH, Leong WQ, Chew MH, et al: Postoperative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer. Anticancer Res 34:7407-7414, 2014
27. Greenhough A, Smartt HJ, Moore AE, et al: The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30:377-386, 2009
28. Gasic GJ, Gasic TB, Murphy S: Anti-metastatic effect of aspirin. Lancet 2:932-933, 1972
29. Brudvik KW, Henjum K, Aandahl EM, et al: Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother 61:1045-1053, 2012
30. Yaqub S, Henjum K, Mahic M, et al: Regulatory T cells in colorectal cancer patients suppress antitumor immune activity in a COX-2 dependent manner.Cancer Immunol Immunother 57:813-821, 2008